Qiagen NV | QIA - Sales Revenues

Stock Price
28.60
Daily Change
0.14 0.47%
Monthly
-18.17%
Yearly
-24.60%
Q2 Forecast
27.85

Qiagen NV reported $419.22M in Sales Revenues for its fiscal quarter ending in March of 2026.





Sales Change Date
Akebia Therapeutics USD 57.62M 1.14M Dec/2025
Alaunos Therapeutics USD 2K 2K Mar/2025
argenx SE USD 1.12B 0 Mar/2026
Avita Medical AUD 17.61M 805K Dec/2025
Dianthus Therapeutics USD 284K 112K Dec/2025
Ionis Pharmaceuticals USD 246M 43M Mar/2026
IQVIA Holdings USD 4.15B 210M Mar/2026
Moderna USD 389M 289M Mar/2026
Organon & Co USD 1.46B 50M Mar/2026
Qiagen NV USD 419.22M 38.16M Mar/2026
Revvity USD 711M 61.06M Mar/2026
Tectonic Therapeutic USD 0 0 Dec/2024
Viatris USD 3.52B 180M Mar/2026
Xeris Pharmaceuticals USD 83.13M 2.68M Mar/2026